Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Last Updated: Friday, July 17, 2026
Results from a multicenter, phase 2 trial demonstrate that itacitinib monotherapy is as effective as systemic corticosteroids in treating low-risk acute GVHD with fewer serious infections.
Advertisement
News & Literature Highlights